media – Page 532 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Pfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

Pfizer Inc. has initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in boys with Duchenne muscular dystrophy (DMD). The first boy received an infusion of the mini-dystrophin gene on March 22nd, administered under the supervision of principal investigator, Edward Smith, MD, Associate Professor of Pediatrics and Neurology at Duke University Medical Center.
- Source: finance.yahoo
- 630
- April 16, 2018
Clinical Trials DMD
Brentuximab Vedotin Approved for Classical HL

The US Food and Drug Administration (FDA) has approved brentuximab vedotin (Adcetris) to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL), in combination with chemotherapy.
- Source: cancernetwork
- 663
- April 16, 2018
ADCETRIS cHL New Approvals
GSK hands rare disease gene therapies over to Orchard

Orchard Therapeutics has snapped up GlaxoSmithKline’s portfolio of approved and investigational rare disease gene therapies. The deal sees GSK become an investor in Orchard, with a 19.9 percent equity stake along with a seat on the firm’s board. The UK drugs giant also stands to receive royalties and commercial milestone payments related to the acquired portfolio.
- Source: pharmatimes
- 665
- April 16, 2018
GSK Market Views rare disease gene therapies
RubrYc Therapeutics Completes $10M Million Series A Financing

RubrYc Therapeutics, Inc., a biotherapeutics discovery business, announced today it has closed a $10 million Series A Preferred Equity financing round led by Third Point Ventures, with participation by Paladin Capital Group and Vital Venture Capital.
- Source: prnewswire
- 930
- April 16, 2018
antibody biotherapeutics Series
A healthcare startup to improve dose management for injectable drugs raises $6.6M

The FDA confirmed in a March 16, 2012 communication released to Bloomberg News that the vaginally placed pelvic mesh product known as the Prolift, sold by Johnson & Johnson subsidiary Ethicon, Inc. since March, 2005, was initially marketed without any clearance or approval from the FDA.
- Source: Med City News
- 515
- April 16, 2018
Company Insights digital health
Oxygen device maker Inogen discloses customer data breach

Oxygen supply device maker Inogen Inc said on Friday it was notifying 30,000 existing and former customers following a data breach that led to improper access of personal details of some rental clients.
- Source: Reuters
- 495
- April 16, 2018
Company Insights cybersecurity EHR
50 percent of EHR-using docs unsatisfied with patient data access

A recent survey of 300 primary care physicians who use EHRs found that half of the respondents wanted better access to patient data.
- Source: MobiHealthNews
- 621
- April 16, 2018
digital health EHR Researches
ARKAY Therapeutics Submits Investigational New Drug (IND) Application for RK-01, a First-in Class ‘Beta-cell-centric’ Drug Combination Product for Type 2 Diabetes

First Human Proof-of-Concept (PoC) Trial to Test the Superiority of RK-01 over Metformin in Type 2 Diabetes Patients with Inadequate Glycemic Control.
- Source: Pipelinereview
- 514
- April 13, 2018
New Approvals type 2 diabetes
Magenta bags $52M Series C for bone marrow transplant pipeline

High-flying Cambridge startup Magenta has snagged $52 million in a new financing round to push forward the company’s pipeline of therapies for bone marrow transplant.
- Source: Endpts
- 477
- April 13, 2018
financing Market Views
Bristol-Myers Squibb and Harvard Announce New Fibrosis Research Collaboration

Bristol-Myers Squibb Company and the Harvard Fibrosis Network of the Harvard Stem Cell Institute today announce a research collaboration to discover and develop potential new therapies for fibrotic diseases, including fibrosis of the liver and heart. The Harvard Fibrosis Network brings together researchers across the schools and affiliated hospitals of Harvard University.
- Source: news.bms
- 599
- April 13, 2018
Bristol-Myers Squibb fibrotic diseases

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.